Advanced Retina Prior Authorization
Outsource specialty retina prior authorization to remote BPO specialists trained on the high-cost, high-criteria therapies that mainstream PA teams miss. Geographic Atrophy inhibitors (Syfovre, Izervay), intravitreal corticosteroid implants (Ozurdex, Iluvien, Retisert, Yutiq), photodynamic therapy (Verteporfin), and Tepezza for Thyroid Eye Disease.
Advanced Retina Prior Authorization, handled by a dedicated remote team
Trained specialists handle it inside your existing software, so your team stays on patient care.
With Staffingly, advanced retina prior authorization outsourcing means a dedicated team of trained specialists running this part of your back office. They are named to your account and work remotely as an extension of your staff, not a shared offshore pool. As a HIPAA-compliant healthcare BPO, we bill a flat weekly fee per specialist, never a percentage of your collections.
Specialty retina PA, where mainstream PA teams stop
Anti-VEGF prior auth is a workflow most billing teams can handle. The advanced retina pipeline is not. Geographic Atrophy inhibitors land in front of payers with growing-lesion documentation requirements. Intravitreal corticosteroid implants need uveitis history that mainstream coders do not recognize. Photodynamic therapy bundles a drug J-code with a procedure CPT and a setting-specific submission. Tepezza for Thyroid Eye Disease is an oculoplastic-adjacent biologic infusion that confuses general PA teams. Our retina-trained PA specialists work these queues every day.
Tell us about your practice.
Send us your situation and our team will scope the right setup, usually within one business day. No obligation.
Advanced retina drugs & procedures we PA every week
Web-verified against AAPC, CMS, AAO, and current payer policies.
J-codes and CPT codes verified against CMS HCPCS Level II, AAPC coding guidance, and AAO injectable drug coding. Payer-specific medical necessity policies still apply.
| HCPCS / CPT | Drug or Procedure | Indication |
|---|---|---|
| J2781 | Pegcetacoplan (Syfovre) | Geographic Atrophy (permanent J-code Oct 1, 2023) |
| J2782 | Avacincaptad pegol (Izervay) | Geographic Atrophy (permanent J-code Apr 1, 2024) |
| J7312 | Dexamethasone intravitreal implant (Ozurdex) | Uveitis, diabetic macular edema, RVO |
| J7313 | Fluocinolone acetonide intravitreal implant (Iluvien) | Diabetic macular edema, chronic uveitis |
| J3396 | Verteporfin (Visudyne) | Photodynamic therapy drug |
| 67221 | Destruction of localized lesion of choroid (PDT) | Submitted with J3396 same date of service |
| 67225 | PDT, second eye | Same-session second-eye treatment |
| J3241 | Teprotumumab (Tepezza) | Thyroid Eye Disease (permanent J-code Oct 1, 2020) |
Three reasons specialty retina PAs land faster with us
FAF + lesion documentation at submission
Geographic Atrophy PAs require fundus autofluorescence imaging showing lesion growth. We package the FAF series, BCVA trend, and prior treatment history before submission so payers do not return for more.
Drug + procedure dual-code packaging
PDT (J3396 + 67221/67225) and intravitreal implants both require coordinated drug-plus-procedure submission. We file both sides aligned so the claim does not bounce on a missing pair.
Tepezza infusion workflow handled
Tepezza (J3241) PA needs ophthalmology + endocrine documentation. We coordinate the TED activity score, prior steroid trial, and infusion site setting so the biologic gets approved without rework.
How we run an advanced retina PA
Clinical packet build
FAF for GA, OCT for steroid implants, fluorescein angiography for PDT, TED activity score for Tepezza. Prior treatment history, ICD-10 specificity, payer policy pulled.
Drug + procedure pairing
For PDT, J3396 and CPT 67221/67225 submitted on same claim. For implants, J7312/J7313 paired with 67028. Tepezza paired with infusion CPT.
Portal submission
Availity, NaviNet, payer portal, or fax. Submission ID logged in EMR.
24-hour follow-up
Status check. Clinical clarification routed to doctor in 60-second loops.
Peer-to-peer ready
P2P slot booked, FAF/OCT/FA staged. Doctor briefed. Many P2Ps handled by retina-trained coordinator.
Approval & scheduling
Approval logged. Drug ordered. Chair time or infusion slot confirmed.
AI + Retina-Trained Clinicians = Faster PA Approvals
Staffingly AI and workflow automation handle the repetitive parts of eye care prior authorization. Form auto-fill, payer rule matching, step-therapy lookups, peer-to-peer scheduling. Every case still reviewed by retina-trained specialists before submission.
AI Clinical Sandbox
Validates anti-VEGF (J0178, J0177, J2778, J2777) and cataract (CPT 66984) PAs against payer rules before submission. Catches missing OCT, BCVA, step therapy.
Same-Day Submission
AI form-fill automation pulls patient data from your EMR. Submission goes out the same day you order, not the same week.
Denial Pattern Analytics
Automation tracks denial reasons by payer, drug, and CPT in real time. Practice gets a monthly denial-pattern report to fix upstream documentation.
Peer-to-Peer Auto-Routing
Automation flags every denial that qualifies for P2P. Coordinator packages OCT progression, FA, BCVA, step therapy. Physician walks into a prepped call.
- HIPAA Compliant
- SOC 2 Type II
- ISO 27001
- End-to-End Encryption
- BAA Before Pilot
How Staffingly works, in practice
Inside the work A trained Staffingly specialist handles the workflow inside your existing practice software, with clear escalation back to your team.
One Flat Weekly Rate. No Surprises.
Dedicated specialists at a fixed weekly cost. Per specialist FTE, per week. No contracts, no minimums, no hidden fees.
Want to compare against an in-house hire? Use the savings calculator.
Frequently asked questions
Which advanced retina drugs do you submit prior auth for?
We submit prior authorization for Syfovre (pegcetacoplan, J2781) and Izervay (avacincaptad pegol, J2782) for Geographic Atrophy; Ozurdex (dexamethasone implant, J7312), Iluvien (fluocinolone, J7313), Retisert and Yutiq for chronic non-infectious uveitis or diabetic macular edema; Verteporfin (Visudyne, J3396) photodynamic therapy submitted with CPT 67221 or 67225; and Tepezza (teprotumumab, J3241) for Thyroid Eye Disease infusions.
What documentation do payers require for Syfovre and Izervay prior auth?
Payers require baseline best-corrected visual acuity (BCVA), lesion measurement via fundus autofluorescence (FAF) showing documented GA lesion area, prior treatment history, and clinical rationale. We package the FAF imaging, ICD-10 specificity, and BCVA trend at submission so the request matches each payer's published medical necessity criteria.
How much does advanced retina PA outsourcing cost?
Staffingly advanced retina PA outsourcing is a flat weekly rate: $399 per PA specialist per week for a single-position engagement, $349 at 5+ specialists, and $299 at 10+ resources. Each specialist works 45 hours per week, fully managed, no long-term contract. The 2-Week Free Pilot is included so you see real GA, steroid implant, PDT, and Tepezza submissions before any invoice.
Do you coordinate Tepezza infusion site logistics?
Yes. Tepezza (J3241) is an infusion biologic for Thyroid Eye Disease. We submit the PA with ophthalmology plus endocrine documentation, coordinate the infusion site (clinic, hospital outpatient, home infusion as covered), and confirm benefit before the first dose. Eight infusion cycles are typical and we calendar each one with re-verification at intake.
President and CEO, Staffingly, Inc. 25+ years in IT consulting and healthcare BPO operations. One of the earliest US operators to set up an RPO/BPO delivery network in India. Leads AI-driven optometry and ophthalmology workflows that help vision practices and multi-location groups cut admin cost without compromising care.
